MMAE

MMAE Full Name

Monomethyl auristatin E

MMAE Introduction

Monomethyl auristatin E (MMAE) is a potent cytotoxic agent commonly used in antibody-drug conjugates (ADCs) for targeted cancer therapy. Upon binding to CD30-expressing cells, the ADC-CD30 complex is internalized, leading to the release of MMAE via proteolytic cleavage. Antibody-drug conjugates (ADCs) are an emerging class of targeted therapies for the treatment of cancer that aim to directly deliver small molecule chemotherapy and kill tumor cells while sparing healthy cells. ADCs mainly contain three parts: monoclonal antibodies, linkers and toxins. Monoclonal antibodies are the key to determining the efficacy of ADC; the linker determines the systemic toxicity and clinical efficacy of ADC drugs; toxins are the key factor that determines the lethality of ADC drugs. Although there are currently more than 130 types of toxins used in announced ADC drugs, there are only 6-8 toxins used in ADC drugs that are in clinical trials or have been marketed. According to the mode of action, they can be roughly divided into three categories: tubulin inhibitors, DNA synthesis inhibitors and topoisomerase inhibitors. Among them, ADC drugs using MMAE in tubulin inhibitors as toxin molecules have been approved the most. Today we focus on the definition of MMAE and its application and mechanism of action in ADC.

In preclinical studies, MMAE has exhibited promising antitumor activity in various cancer models, including prostate cancer, pancreatic cancer, and gastric cancer. Additionally, MMAE conjugates have shown improved therapeutic indices compared to free MMAE, as evidenced by a 10-fold increase in the maximum tolerated dose for PSMA-1-VcMMAE in comparison to PSMA-ADC. Moreover, the use of MMAE-linked ADCs targeting tumor endothelial marker 8 (TEM8) has been described, highlighting the potential of MMAE in stromal-targeted cancer therapy. However, it is important to note that MMAE's high toxicity necessitates precise targeting to tumors to minimize off-target effects. Studies have explored various strategies to achieve this, including the development of peptide conjugates and ADCs. Additionally, the use of protease-cleavable linkers in ADCs has been shown to modulate the anticancer activity of non-internalizing ADCs, leading to the release of MMAE in the subendothelial extracellular matrix, thereby enhancing their anti-cancer activity.

In conclusion, the potent cytotoxicity of MMAE, when harnessed in ADCs, holds great promise for targeted cancer therapy. However, the development of precise targeting strategies and the use of cleavable linkers are crucial for maximizing its therapeutic potential while minimizing systemic toxicity.

Alternate Names for MMAE

Monomethyl auristatin E; MMAE Antibody Drug Conjugate; MMAE

• Anti-Cytotoxic Payloads Antibodies
• Anti-Cytotoxic Payloads Antibodies
• High Quality Reagents for MMAE ADC Research and Development
• High Quality Reagents for MMAE ADC Research and Development
• High Quality Reagents for MMAE ADC Research and Development
• High Quality Reagents for MMAE ADC Research and Development

• 1. Barbara Bernardim., et al. Cathepsin B Processing Is Required for the In Vivo Efficacy of Albumin–Drug Conjugates. Bioconjugate Chemistry Article ASAP. 2024